Eledon Pharmaceuticals (ELDN) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company background and strategy

• Focuses on anti-CD40 ligand therapy to prevent immune rejection in organ transplantation, with lead asset tegoprubart advanced since 2020.

• Three ongoing kidney transplant trials: phase 1b, phase 2, and a long-term extension, aiming to replace tacrolimus.

• Additional phase 2 trial in islet cell transplantation and involvement in xenotransplantation with successful human procedures.

• Market opportunity includes about 50,000 annual US transplants, with kidney transplants as the largest segment.

• Small number of transplant centers allows for a targeted commercial approach despite large revenue potential.

Clinical program and upcoming milestones

• Phase 1b kidney transplant study showed eGFR improvements of 30–90% over historical standard of care; next update expected mid-next year.

• Phase 2 kidney transplant trial (120 patients) completed enrollment ahead of schedule; data readout expected in Q4 next year.

• Islet cell phase 2 trial enrolling as planned, targeting high-risk type 1 diabetes; full data on nine patients expected in about a year.

• Both kidney and islet cell studies focus on efficacy (eGFR, A1C) and safety endpoints, aiming to avoid tacrolimus-related toxicities.

• Positive data could lead to phase 3 discussions with the FDA within a year.

Competitive landscape and differentiation

• Competing anti-CD40 ligand programs from Sanofi, Biogen/UCB, and Amgen target other autoimmune diseases, not transplantation.

• Tegoprubart and Sanofi’s antibody share similar IgG1 structure with modified Fc function; Biogen/UCB and Amgen use different formats.

• Tegoprubart demonstrates longer half-life and no observed antidrug antibodies compared to competitors.

• Initial administration will be IV every three weeks, with subcutaneous formulation developed but not required for transplant patients.